Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
3.000
-0.130 (-4.15%)
At close: Nov 16, 2026, 4:00 PM EST
2.960
-0.040 (-1.33%)
After-hours: Nov 16, 2026, 7:30 PM EST
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $234.13K in the quarter ending September 30, 2026, a decrease of -93.43%. This brings the company's total for the last twelve months to $4.69M, up 17.59% year-over-year. In the year 2025, Coya Therapeutics had annual revenue of $7.95M with 123.57% growth. That makes Coya Therapeutics the 40,218th largest company in the world by revenue and 5,346th in the United States.
Revenue (ttm)
$4.69M
Revenue Growth
+17.59%
P/S Ratio
15.01
Revenue / Employee
$586,128
Employees
8
Market Cap
70.37M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.95M | 4.39M | 123.57% |
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Rani Therapeutics Holdings | 6.58M |
| NeurAxis | 6.53M |
| Milestone Pharmaceuticals | 5.31M |
| Atara Biotherapeutics | 3.97M |
| Nutriband | 1.62M |
| MediciNova | 935.72K |
COYA News
- 6 days ago - Coya Therapeutics reports Q3 EPS (45c), consensus (35c) - TheFly
- 6 days ago - Coya Therapeutics sees cash runway into 2H27 - TheFly
- 6 days ago - Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update - Business Wire
- 6 days ago - Coya Therapeutics Earnings release: Q3 2026 - Filings
- 6 days ago - Coya Therapeutics Quarterly report: Q3 2026 - Filings
- 6 days ago - Coya Therapeutics Slides: Investor presentation - Filings
- 19 days ago - Coya Therapeutics announces poster presentation on NfL biomarker methodology - TheFly
- 19 days ago - Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting - Business Wire